Wang, Yongjun
Johnston, Claiborne http://orcid.org/0000-0002-2912-0714
Bath, Philip M
Meng, Xia
Jing, Jing
Xie, Xuewei http://orcid.org/0000-0001-8154-1957
Wang, Anxin http://orcid.org/0000-0003-4351-2877
Pan, Yuesong http://orcid.org/0000-0003-3082-6789
Xu, Anding http://orcid.org/0000-0003-3154-0985
Dong, Qiang
Wang, Yilong
Zhao, Xingquan
Li, Zixiao
Clinical trials referenced in this document:
Documents that mention this clinical trial
Analytical validation of GMEX rapid point-of-care<i>CYP2C19</i>genotyping system for the CHANCE-2 trial
https://doi.org/10.1136/svn-2021-000874
Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a subgroup analysis of the CHANCE-2 trial (Results)
https://doi.org/10.1136/svn-2023-002450
Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial
https://doi.org/10.1136/svn-2020-000791
Effect of Hypertension on Efficacy and Safety of Ticagrelor-Aspirin Versus Clopidogrel-Aspirin in Minor Stroke or Transient Ischemic Attack
https://doi.org/10.1161/strokeaha.122.038662
Stroke Recurrence and Antiplatelets in Posterior Versus Anterior Circulation Minor Stroke or Transient Ischemic Attack
https://doi.org/10.1161/strokeaha.122.041738
Dual Antiplatelet Therapies and Causes in Minor Stroke or Transient Ischemic Attack: A Prespecified Analysis in the CHANCE-2 Trial
https://doi.org/10.1161/strokeaha.122.042233
Funding for this research was provided by:
National Science and Technology Major Project (2017ZX09304018)